首款！GSK RSV疫苗获FDA批准扩大适用人群至50-59岁

2024-06-12

6月7日，葛兰素史克（GSK）宣布，FDA批准重组呼吸道合胞病毒（RSV）疫苗Arexvy的适用范围扩大到50-59岁的RSV高危成人。这是首款保护50-59岁高危人群的RSV疫苗。Arexvy已于2023年先后在美国和欧洲获批上市，用于60岁及以上成人预防由RSV引起的下呼吸道疾病（LRTD）。

Pre: Over $2 billion! Takeda introduces an anti-Aβ vaccine

Next: My first! The GSK RSV vaccine has been approved by the FDA to be extended to age 50-59

We would like to use cookies to better understand your use of this website, which will help improve your experience on future visits to the website. You can change this setting in your browser settings. For more information about the use of cookies, please refer to our Privacy Policy.

Copyright © 2010-2024 Fluoropharm Co.,Ltd. All rights reserved.

浙ICP备2023037538号-1